問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

Recruiting

List

582Cases

2024-07-01 - 2027-12-31

Phase III

Active
Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    placebo ‧ BI 690517 Empagliflozin

Participate Sites
23Sites

Recruiting23Sites

2016-03-01 - 2023-09-01

Phase III

An open-label, randomized, controlled phase III trial evaluating the efficacy and safety of EndoTAG-1 in combination with paclitaxel and gemcitabine compared to paclitaxel and gemcitabine as first-line therapy in patients with visceral metastatic triple-negative breast cancer

  • Condition/Disease

    visceral metastatic triple-negative breast cancer

  • Test Drug

    EndoTAG-1

Participate Sites
3Sites

Recruiting3Sites

2018-11-01 - 2021-01-31

Phase II

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 Days and <=3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection

  • Condition/Disease

    Respiratory Syncytial Virus(RSV) Infection

  • Test Drug

    JNJ-53718678/Placebo

Participate Sites
6Sites

Recruiting6Sites

2017-01-01 - 2021-12-31

Phase III

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Olaparib

Participate Sites
9Sites

Recruiting5Sites

Terminated4Sites

2018-01-22 - 2019-12-31

Phase III

A Randomized, Double-Blinded, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

  • Condition/Disease

    Acute Ischemic Stroke or Transient ischaemic attack

  • Test Drug

    BRILINTA

Participate Sites
16Sites

Recruiting15Sites

Study ended1Sites

李宗海
Linkou Chang Gung Medical Foundation

Division of Neurology

林秀芬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

  • Condition/Disease

    Severe eosinophilic leukocyte asthma

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

2018-11-19 - 2022-12-01

Phase III

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Test Drug

    dapagliflozin film-coated tablets

Participate Sites
15Sites

Recruiting13Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2021-06-01 - 2023-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-06-17 - 2021-12-31

Others

A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy, in Combination with Concurrent Chemotherapy for Patients with Locally Advanced or Unresectable Rectal Cancer

  • Condition/Disease

    The pathological diagnosis is confirmed as rectal adenocarcinoma, T3~T4, N any, M0 .The distal boundary of the tumor to the anal opening must be less than or equal to 10 cm.

  • Test Drug

    PEP503

Participate Sites
3Sites

Recruiting3Sites

2017-04-15 - 2018-08-27

Phase I

A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRONICALLY INFECTED WITH HEPATITIS B VIRUS

  • Condition/Disease

    HEPATITIS B VIRUS

  • Test Drug

    RO7049389

Participate Sites
7Sites

Recruiting6Sites

葉昭廷
Linkou Chang Gung Medical Foundation

1 50 51 52 53 54 59
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB